Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
University of Tennessee Cancer Institute
283
mi
from 43215
Knoxville, TN
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
University of Tennessee Cancer Institute
283
mi
from 43215
Knoxville, TN
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Texas Oncology - Baylor Charles A. Simmons Cancer Center
909
mi
from 43215
Dallas, TX
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Texas Oncology - Baylor Charles A. Simmons Cancer Center
909
mi
from 43215
Dallas, TX
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Hope Oncology
900
mi
from 43215
Richardson, TX
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Hope Oncology
900
mi
from 43215
Richardson, TX
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Fletcher Allen Health Care
590
mi
from 43215
Burlington, VT
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine, Part A
Status: Archived
Updated: 1/1/1970
Fletcher Allen Health Care
590
mi
from 43215
Burlington, VT
Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
A Pilot Study to Evaluate the Effects of Antiangiogenic Factor as an Adjunct Treatment After Photoangiolysis in Patients With Bilateral Recurrent Respiratory Papillomatosis of the Vocal Fold
Status: Archived
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
A Pilot Study to Evaluate the Effects of Antiangiogenic Factor as an Adjunct Treatment After Photoangiolysis in Patients With Bilateral Recurrent Respiratory Papillomatosis of the Vocal Fold
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Modulation of Arachidonic Acid Metabolism by Chemopreventive Agents in Smokers
Modulation of Arachidonic Acid Metabolism by Chemopreventive Agents in Smokers
Status: Archived
Cornell University, Weill Medical College
480
mi
from 43215
New York, NY
Modulation of Arachidonic Acid Metabolism by Chemopreventive Agents in Smokers
Modulation of Arachidonic Acid Metabolism by Chemopreventive Agents in Smokers
Status: Archived
Updated: 1/1/1970
Cornell University, Weill Medical College
480
mi
from 43215
New York, NY
Study to Evaluate the Diagnostic Value of a Combined Molecular Breast Imaging/ Breast Tomosynthesis Modality
Pilot Study to Evaluate the Incremental Diagnostic Value of a Combined Molecular Breast Imaging / Breast Tomosynthesis Modality
Status: Archived
Mayo Clinic College of Medicine
559
mi
from 43215
Rochester, MN
Study to Evaluate the Diagnostic Value of a Combined Molecular Breast Imaging/ Breast Tomosynthesis Modality
Pilot Study to Evaluate the Incremental Diagnostic Value of a Combined Molecular Breast Imaging / Breast Tomosynthesis Modality
Status: Archived
Updated: 1/1/1970
Mayo Clinic College of Medicine
559
mi
from 43215
Rochester, MN
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
449
mi
from 43215
Basking Ridge, NJ
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
449
mi
from 43215
Basking Ridge, NJ
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma
Status: Archived
UCSF Helen Diller Family Comprehensive Cancer Center
2108
mi
from 43215
San Francisco, CA
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
UCSF Helen Diller Family Comprehensive Cancer Center
2108
mi
from 43215
San Francisco, CA
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma
Status: Archived
Huntsman Cancer Hospital
1511
mi
from 43215
Salt Lake City, UT
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
A Study Evaluating Safety and Efficacy of Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Adenocarcinoma
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
1511
mi
from 43215
Salt Lake City, UT
A Comparison of Methods to Detect Polyps During Colonoscopy
Comparison of Detection of Polyps During Both Insertion and Withdrawal Phases of Colonoscopy Versus the Standard Practice of Detection of Polyps During the Withdrawal Phase of Colonoscopy: A Prospective Quality Improvement Study
Status: Archived
Cleveland Clinic Florida
971
mi
from 43215
Weston, FL
A Comparison of Methods to Detect Polyps During Colonoscopy
Comparison of Detection of Polyps During Both Insertion and Withdrawal Phases of Colonoscopy Versus the Standard Practice of Detection of Polyps During the Withdrawal Phase of Colonoscopy: A Prospective Quality Improvement Study
Status: Archived
Updated: 1/1/1970
Cleveland Clinic Florida
971
mi
from 43215
Weston, FL
Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging
Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging
Status: Archived
Mayo Clinic Rochester
559
mi
from 43215
Rochester, MN
Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging
Effect of Surgery and Radiation Therapy on Tc-99M Sestamibi Uptake Patterns in Molecular Breast Imaging
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
559
mi
from 43215
Rochester, MN
Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain
UMCC 2008.62: Prospective Pilot Study Evaluating the Use of Duloxetine for Treatment of Aromatase Inhibitor-associated Musculoskeletal Symptoms in Breast Cancer Patients
Status: Archived
University of Michigan Comprehensive Cancer Center
164
mi
from 43215
Ann Arbor, MI
Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain
UMCC 2008.62: Prospective Pilot Study Evaluating the Use of Duloxetine for Treatment of Aromatase Inhibitor-associated Musculoskeletal Symptoms in Breast Cancer Patients
Status: Archived
Updated: 1/1/1970
University of Michigan Comprehensive Cancer Center
164
mi
from 43215
Ann Arbor, MI
A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
A Dose Tolerability and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
Status: Archived
Baptist Cancer Center
671
mi
from 43215
Jacksonville, FL
A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
A Dose Tolerability and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
Baptist Cancer Center
671
mi
from 43215
Jacksonville, FL
A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
A Dose Tolerability and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
Status: Archived
Orchard Health Care Research
284
mi
from 43215
Niles, IL
A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
A Dose Tolerability and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
Orchard Health Care Research
284
mi
from 43215
Niles, IL
A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
A Dose Tolerability and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
Status: Archived
Texas Oncology, P.A. - Bedford
925
mi
from 43215
Bedford, TX
A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
A Dose Tolerability and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
Texas Oncology, P.A. - Bedford
925
mi
from 43215
Bedford, TX
A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
A Dose Tolerability and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
Status: Archived
Texas Oncology Wichita Falls Texoma
955
mi
from 43215
Wichita, TX
A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
A Dose Tolerability and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
Status: Archived
Updated: 1/1/1970
Texas Oncology Wichita Falls Texoma
955
mi
from 43215
Wichita, TX
To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors
An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors
Status: Archived
Clinical Trial Facility
332
mi
from 43215
Nashville, TN
To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors
An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
332
mi
from 43215
Nashville, TN
To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors
An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors
Status: Archived
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors
An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1065
mi
from 43215
Austin, TX
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258, and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Archived
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258, and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258, and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Archived
David Geffen School of Medicine, UCLA
1982
mi
from 43215
Los Angeles, CA
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258, and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
David Geffen School of Medicine, UCLA
1982
mi
from 43215
Los Angeles, CA
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258, and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Archived
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258, and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258, and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Archived
Sarah Cannon Cancer Center
333
mi
from 43215
Nashville, TN
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258, and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
333
mi
from 43215
Nashville, TN
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258, and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Archived
Huntsman Cancer Hospital
1511
mi
from 43215
Salt Lake City, UT
Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors
A Randomized, Open-label, Multi-center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulations of TKI258, and the Effect of Food on the Bioavailability of TKI258, in Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
1511
mi
from 43215
Salt Lake City, UT
Detection of Cervical Lymph Node Metastases With a High-Resolution Positron Emission Tomography (PET) Imaging System
Feasibility Study for Detection of Cervical Lymph Node Metastases With a High-Resolution PET Imaging System in Patients With Known or Suspected Cancers of the Upper Aerodigestive Tract
Status: Archived
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Detection of Cervical Lymph Node Metastases With a High-Resolution Positron Emission Tomography (PET) Imaging System
Feasibility Study for Detection of Cervical Lymph Node Metastases With a High-Resolution PET Imaging System in Patients With Known or Suspected Cancers of the Upper Aerodigestive Tract
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver
Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver
Status: Archived
University of New Mexico Cancer Center
1332
mi
from 43215
Albuquerque, NM
Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver
Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver
Status: Archived
Updated: 1/1/1970
University of New Mexico Cancer Center
1332
mi
from 43215
Albuquerque, NM
Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
Collection of Biospecimen and Clinical Information in Patients With Gastrointestinal Cancers
Status: Archived
Stanford university Hospital and Clinics
2100
mi
from 43215
Stanford, CA
Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
Collection of Biospecimen and Clinical Information in Patients With Gastrointestinal Cancers
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
2100
mi
from 43215
Stanford, CA
Confocal Laser Endomicroscopy for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia
Status: Archived
Mayo Clinic - Division of Nephrology
559
mi
from 43215
Rochester, MN
Confocal Laser Endomicroscopy for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia
Status: Archived
Updated: 1/1/1970
Mayo Clinic - Division of Nephrology
559
mi
from 43215
Rochester, MN
Confocal Laser Endomicroscopy for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia
Status: Archived
University of Chicago
270
mi
from 43215
Chicago, IL
Confocal Laser Endomicroscopy for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia
Status: Archived
Updated: 1/1/1970
University of Chicago
270
mi
from 43215
Chicago, IL
Confocal Laser Endomicroscopy for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia
Status: Archived
Atlanta VA Medical Center
430
mi
from 43215
Decatur, GA
Confocal Laser Endomicroscopy for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia
Status: Archived
Updated: 1/1/1970
Atlanta VA Medical Center
430
mi
from 43215
Decatur, GA
Confocal Laser Endomicroscopy for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia
Status: Archived
University of Washington Medical Center
2005
mi
from 43215
Seattle, WA
Confocal Laser Endomicroscopy for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia
Status: Archived
Updated: 1/1/1970
University of Washington Medical Center
2005
mi
from 43215
Seattle, WA
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Status: Archived
Stanford university Hospital and Clinics
2100
mi
from 43215
Stanford, CA
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
2100
mi
from 43215
Stanford, CA
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Status: Archived
Florida Cancer Specialists
925
mi
from 43215
Fort Myers, FL
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Florida Cancer Specialists
925
mi
from 43215
Fort Myers, FL
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Status: Archived
Northeast Georgia Heart Center, PC
393
mi
from 43215
Gainesville, FL
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Northeast Georgia Heart Center, PC
393
mi
from 43215
Gainesville, FL
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Status: Archived
Tennessee Oncology, PLLC
348
mi
from 43215
Nashville, TN
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Status: Archived
Updated: 1/1/1970
Tennessee Oncology, PLLC
348
mi
from 43215
Nashville, TN
Proton Beam Radiation Therapy in Treating Patients With Retroperitoneal Sarcoma
Proton Radiotherapy for Retroperitoneal Sarcoma
Status: Archived
Abamson Cancer Center of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Proton Beam Radiation Therapy in Treating Patients With Retroperitoneal Sarcoma
Proton Radiotherapy for Retroperitoneal Sarcoma
Status: Archived
Updated: 1/1/1970
Abamson Cancer Center of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
1610
mi
from 43215
Sedona, AZ
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1610
mi
from 43215
Sedona, AZ
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
1638
mi
from 43215
Tucson, AZ
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1638
mi
from 43215
Tucson, AZ
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
1158
mi
from 43215
Denver, CO
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1158
mi
from 43215
Denver, CO
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
791
mi
from 43215
Ocoee, FL
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
791
mi
from 43215
Ocoee, FL
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
165
mi
from 43215
Carmel, IN
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
165
mi
from 43215
Carmel, IN
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
624
mi
from 43215
Minneapolis, MN
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
624
mi
from 43215
Minneapolis, MN
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
499
mi
from 43215
Columbia, MO
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
499
mi
from 43215
Columbia, MO
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
619
mi
from 43215
Kansas City, MO
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
619
mi
from 43215
Kansas City, MO
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
1756
mi
from 43215
Henderson, NV
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1756
mi
from 43215
Henderson, NV
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
521
mi
from 43215
Troy, NY
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
521
mi
from 43215
Troy, NY
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
2055
mi
from 43215
Eugene, OR
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2055
mi
from 43215
Eugene, OR
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
2023
mi
from 43215
Portland, OR
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2023
mi
from 43215
Portland, OR
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Clinical Research Facility
384
mi
from 43215
Kingston, PA
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients With Previously Treated Metastatic Breast Cancer (MBC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
384
mi
from 43215
Kingston, PA